Adrovance (Alendronic Acid / Colecalciferol)

What Is Adrovance and What Is It Used For?

Osteoporosis is a condition in which bones become thin, weak, and fragile, making them more likely to break. It is especially common after menopause because the protective effects of estrogen on bone decline rapidly. The World Health Organization (WHO) estimates that osteoporosis affects approximately 200 million women worldwide, and one in three women over 50 will experience an osteoporotic fracture in their lifetime.

Adrovance addresses two key components of osteoporosis management simultaneously. The first active ingredient, alendronic acid, belongs to a class of medicines called bisphosphonates. It works by binding to bone tissue and inhibiting the activity of osteoclasts, the cells responsible for breaking down bone. By slowing this natural bone resorption process, alendronic acid allows bone-forming cells (osteoblasts) to work more effectively, gradually increasing bone mineral density (BMD) over time.

The second active ingredient, colecalciferol (vitamin D3, 2800 IU per tablet), provides weekly vitamin D supplementation. Vitamin D is essential for calcium absorption in the gut and for maintaining adequate calcium and phosphate levels needed for proper bone mineralization. Vitamin D deficiency is extremely common in postmenopausal women, particularly in those living at higher latitudes, those with limited sun exposure, and those with darker skin pigmentation. Studies show that up to 50–70% of osteoporosis patients have suboptimal vitamin D levels, which can undermine the effectiveness of bisphosphonate treatment.

By combining both ingredients in a single tablet, Adrovance simplifies treatment and helps ensure that patients receive adequate vitamin D alongside their bone-protective therapy. The European Medicines Agency (EMA) approved this combination because clinical evidence demonstrates that vitamin D repletion is important for maximizing the fracture-reducing benefits of bisphosphonate therapy.

Indications

Adrovance is specifically indicated for the treatment of osteoporosis in postmenopausal women who are at risk of vitamin D insufficiency. It reduces the risk of vertebral (spine) and hip fractures. It is not indicated for use in men, premenopausal women, or children, although alendronic acid alone may be prescribed for some of these groups in certain clinical situations.

What Should You Know Before Taking Adrovance?

Contraindications

Adrovance must not be used in the following situations:

• Esophageal abnormalities that delay emptying, such as stricture or achalasia
• Inability to stand or sit upright for at least 30 minutes after taking the tablet
• Hypocalcaemia (low blood calcium levels) — this must be corrected before starting treatment
• Hypersensitivity to alendronic acid, colecalciferol, or any of the excipients
• Severe renal impairment (creatinine clearance below 35 mL/min)

Warnings and Precautions

Several important warnings apply to Adrovance use. The most significant concern is upper gastrointestinal adverse events. Alendronic acid can cause irritation, inflammation, and even ulceration of the esophagus, stomach, and duodenum. This is why strict adherence to the dosing instructions is critical. Patients who cannot remain upright for 30 minutes, who have difficulty swallowing, or who have active upper gastrointestinal disease should discuss alternative treatments with their doctor.

Osteonecrosis of the jaw (ONJ) is a rare but serious side effect that has been reported with bisphosphonate therapy. The risk is higher with intravenous bisphosphonates used in cancer treatment, but cases have also occurred with oral bisphosphonates like alendronic acid. Patients should have a dental examination before starting treatment, and invasive dental procedures should be avoided during treatment where possible. Risk factors for ONJ include cancer, chemotherapy, corticosteroid use, poor oral hygiene, and pre-existing dental disease.

Atypical femoral fractures have been reported in patients on long-term bisphosphonate therapy (usually more than 3–5 years). These are unusual fractures of the thigh bone that can occur with minimal or no trauma. Patients should report any thigh, hip, or groin pain to their doctor, as this may be an early symptom. If an atypical fracture is suspected, bisphosphonate treatment should be reassessed.

Patients with other conditions that affect mineral metabolism, such as vitamin D deficiency (beyond what the colecalciferol in Adrovance can address), hypoparathyroidism, or malabsorption syndromes, may need additional supplementation or monitoring. The 2800 IU of vitamin D3 in Adrovance may not be sufficient for patients with severe vitamin D deficiency, and additional supplementation may be required.

Pregnancy and Breastfeeding

Adrovance is intended exclusively for postmenopausal women and should not be used during pregnancy or breastfeeding. There are no adequate studies in pregnant women. Animal studies have shown adverse effects on fetal bone development. Bisphosphonates are incorporated into the bone matrix and may be gradually released over years, so the potential for fetal harm exists even after stopping treatment. Women of childbearing potential should discuss this with their doctor before starting any bisphosphonate.

How Does Adrovance Interact with Other Drugs?

Drug interactions with Adrovance primarily involve the alendronic acid component and its absorption characteristics. Alendronic acid has very low oral bioavailability (approximately 0.6% under fasting conditions), and this is further reduced by food and other substances. Understanding these interactions is essential for getting the full benefit of the medication.

Major Interactions

The most clinically significant interactions affect the absorption of alendronic acid:

Food and Beverage Interactions

Food and beverages (including mineral water, coffee, tea, and juice) significantly reduce the absorption of alendronic acid. Even taking it with coffee reduces absorption by approximately 60%. This is why the tablet must be taken with plain water only, at least 30 minutes before the first food, beverage, or other medication of the day.

Vitamin D Interactions

Since Adrovance contains colecalciferol, patients taking additional vitamin D supplements should inform their doctor to avoid excessive vitamin D intake. Olestra, mineral oil, orlistat (a weight-loss medication), and cholestyramine (a cholesterol-lowering medication) can reduce the absorption of vitamin D. Anticonvulsants such as phenytoin and phenobarbital may increase the metabolism of vitamin D, potentially reducing its effectiveness.

What Is the Correct Dosage of Adrovance?

Adults (Postmenopausal Women)

The importance of following these instructions precisely cannot be overstated. The specific timing and positioning requirements exist because alendronic acid can cause serious irritation or ulceration of the esophagus if it does not pass quickly into the stomach. Taking the medication with anything other than plain water, lying down too soon, or not drinking enough water all increase the risk of esophageal injury.

Children

Adrovance is not recommended for use in children or adolescents under 18 years of age. The safety and efficacy of this combination product have not been established in pediatric populations. There is insufficient experience in this age group to support its use.

Elderly

No dose adjustment is required for elderly patients. In clinical trials, there was no age-related difference in efficacy or safety profiles. However, since Adrovance is specifically indicated for postmenopausal women, the typical patient population is older adults. Ensure that elderly patients can remain upright for 30 minutes and can swallow the tablet whole with adequate water. For frail elderly patients who may have difficulty with the dosing requirements, alternative treatments should be considered.

Renal Impairment

No dose adjustment is needed for patients with a creatinine clearance above 35 mL/min. Adrovance is contraindicated in patients with severe renal impairment (creatinine clearance below 35 mL/min) because the kidney plays a role in eliminating alendronic acid and metabolizing vitamin D.

Missed Dose

Overdose

Duration of Treatment

The optimal duration of bisphosphonate treatment is a subject of ongoing medical discussion. Current guidelines from the International Osteoporosis Foundation (IOF) and the American Association of Clinical Endocrinologists (AACE) recommend reassessing the need for continued treatment after 3–5 years. For patients at moderate fracture risk, a “drug holiday” (temporary pause in treatment) may be considered after 5 years. For patients at high fracture risk, continued treatment beyond 5 years may be appropriate. Your doctor will use bone density scans and fracture risk assessments (such as FRAX) to guide this decision.

What Are the Side Effects of Adrovance?

Like all medicines, Adrovance can cause side effects, although not everyone experiences them. The side effects listed here are based on clinical trials and post-marketing surveillance data compiled by the EMA and national regulatory authorities. Most side effects are mild to moderate and often improve as the body adjusts to the medication.

It is important to understand that many of the gastrointestinal side effects can be minimized or prevented by following the dosing instructions carefully. Taking Adrovance with a full glass of plain water, remaining upright, and waiting before eating all help protect the esophagus and stomach lining.

Musculoskeletal pain (bone, joint, or muscle pain) is the most commonly reported side effect. In some patients, this pain can be severe and may occur within days, months, or years after starting treatment. If severe musculoskeletal pain develops, discuss with your doctor whether to continue treatment.

If you experience any side effects, especially severe or persistent ones, inform your doctor or pharmacist. You can also report side effects directly to your national regulatory authority (e.g., the EMA’s EudraVigilance system, the FDA’s MedWatch program, or the MHRA’s Yellow Card Scheme in the UK).

How Should You Store Adrovance?

Proper storage of Adrovance is important to maintain the effectiveness and safety of the medication, particularly because it contains colecalciferol (vitamin D3), which is sensitive to light and moisture degradation.

• Temperature: Store below 25°C (77°F). Do not freeze.
• Packaging: Keep the tablets in the original blister packaging until you are ready to take them. The aluminum blister protects against moisture and light.
• Light: Protect from light. Do not store in direct sunlight.
• Moisture: Store in a dry place. Do not store in the bathroom.
• Children: Keep out of the sight and reach of children.
• Expiry: Do not use after the expiry date printed on the carton and blister. The expiry date refers to the last day of that month.

Do not dispose of unused or expired tablets via household waste or wastewater. Return them to your pharmacy for proper disposal. This helps protect the environment. If you notice any change in the appearance of the tablets (discoloration, crumbling, unusual odor), do not take them and consult your pharmacist.

What Does Adrovance Contain?

Active Ingredients

• Alendronic acid 70 mg (as alendronate sodium trihydrate, equivalent to 91.37 mg alendronate sodium trihydrate) — a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption
• Colecalciferol (vitamin D3) 2800 IU (70 micrograms) — a fat-soluble vitamin essential for calcium absorption and bone mineralization

Inactive Ingredients (Excipients)

The tablet also contains the following inactive ingredients:

• Microcrystalline cellulose
• Lactose anhydrous
• Medium-chain triglycerides
• Gelatin
• Croscarmellose sodium
• Sucrose
• Colloidal silicon dioxide
• Magnesium stearate
• Butylated hydroxytoluene (E321)
• Modified starch (maize)
• Sodium aluminium silicate

Appearance

Adrovance 70 mg/2800 IU tablets are modified capsule-shaped, white to off-white tablets. They are marked with a bone outline on one side and “710” on the other. They are available in blister packs of 2, 4, 6, or 12 tablets (not all pack sizes may be marketed in every country).